ArticleClinicoEconomics and outcomes research : CEOR2021

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.

Mondher Mtibaa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.